Treating non-ulcer dyspepsia and H pylori: It is economically and clinically sensible but it won't make most patients better

BMJ

Volumn 321, Issue 7262, 2000, Pages 648-649

  Van Zanten, Sander J O Veldhuyzen ^a  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DYSPEPSIA; EDITORIAL; ENDOSCOPY; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; PRIORITY JOURNAL; STOMACH CANCER;

ANTIBIOTICS; COST-BENEFIT ANALYSIS; DYSPEPSIA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMAN; META-ANALYSIS;

EID: 0034675233     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.321.7262.648     Document Type: Editorial

References (13)

1. Veldhuyzen van Zanten SJO, Sherman PM. Helicobacter pylori infection as the cause of gastritis, duodenal ulcer, gastric cancer and non-ulcer dyspepsia: a systematic overview. Can Med Assoc J 1994; 150: 177–185.
2. Talley NJ, Hunt RH. What role does H. pylori play in dyspepsia and non-ulcer dyspepsia: arguments for and against H. pylori being associated with dyspeptic symptoms. Gastroenterology 1997; 113(suppl): S67–S77.
3. Armstrong D. H. pylori and dyspepsia. Scand J Gastroenterol 1996; 31(suppl 215): 38–47.
4. Moayyedi P, Soo S, Deeks J, Forman D, Mason J, Innes M, et al. Systematic review and economic evaluation of Helicobacter pylori eradication therapy for non-ulcer dyspepsia. BMJ 2000; 321: 659–664.
5. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999; 45(suppl II): S1137–S1141.
6. Talley NJ, Silverstein MC, Agreus L, Nyren O, Sonnenberg A, Holtmann G. AGA technical review: evaluation of dyspepsia. Gastroenterology 1998; 114: 582–595.
7. Veldhuyzen van Zanten SJO, Cleary C, Talley NJ, Peterson TC, Nyren O, Bradley LA, et al. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol 1996; 91: 660–671.
8. Sonnenberg A. Cost-benefit analysis of testing for H. pylori in dyspeptic subjects. Am J Gastroenterol 1996; 91: 1773–1777.
9. Ofman JJ, Etchason J, Fullerton S, Kahn KL, Soll AH. Management strategies for H. pylori-seropositive patients with dyspepsia: clinical and economic consequences. Ann Intern Med 1997; 126: 280–291.
10. Marshall JK, Armstrong D, O'Brien BJ. Test-and-treat strategies for Helicobacter pylori in uninvestigated dyspepsia: a Canadian economic analysis. Can J Gastroenterol 2000; 14: 379–388.
11. Hunt RH, Thomson ABR consensus conference participants. Canadian Helicobacter pylori consensus conference. Can J Gastroenterol 1998; 12: 31–41.
12. Chiba N, Veldhuyzen van Zanten SJO, Sinclair P, Ferguson RA, Escobedo SR the Cadet-Hp Study Group. Beneficial effect of H. pylori eradication therapy on long term symptom relief in primary care patients with uninvestigated dyspepsia: the cadet-Hp study [abstract]. Gastroenterology 2000; 118(suppl 2): A2390.
13. Veldhuyzen van Zanten SJO, Flook N, Chiba N, Armstrong D, Barkun A, Bradette M, et al. Canadian Dyspepsia Working Group: an evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Can Med Assoc J 2000; 162(suppl 12): 3–23S.